Genetic Signatures Limited (ASX: GSS), a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary 3base® platform technology, has announced its decision not to proceed with the proposed merger with Microba Life Sciences Limited (ASX: MAP). The company designs and manufactures real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under its EasyScreen™ brand. The decision follows Microba’s notification that it lacks the financial capacity to complete the proposed merger without securing additional capital, as outlined in an announcement dated 18 November 2026.
GSS referred to its earlier announcement from 21 October 2026, which detailed an update to the commercial terms of the proposed merger. The move to terminate the agreement comes after many months of extensive discussions, engagement, and due diligence between the two parties. Microba Life Sciences had also requested a voluntary suspension of trading in its shares on 17 November 2026, preceding GSS’s announcement.
Genetic Signatures had engaged in discussions with Microba regarding the potential provision of unsecured debt funding to support Microba’s working capital requirements during the implementation phase of the proposed merger. However, the GSS Board ultimately determined that proceeding with such an arrangement was not viable, citing associated risks and potential regulatory requirements as key considerations.
As a direct consequence of this decision, Genetic Signatures will issue a separate announcement shortly to formally withdraw Resolution 4 from the agenda of its upcoming Annual General Meeting, scheduled for 30 November 2026. Furthermore, GSS will provide a subsequent market update detailing the impact of this announcement and the withdrawal of Resolution 4 on the Takeovers Panel Application initiated by BCAL Diagnostics Limited on 13 November 2026.
